Ahead of Hong Kong list­ing changes, WuXi preps for a biotech boom with a new R&D cen­ter in Shang­hai

Bet­ting on the biotech boom that’s now fo­cus­ing con­sid­er­able at­ten­tion on Chi­na, WuXi AppTec has dou­bled down on its in­vest­ment in one of its Shang­hai com­plex­es.

The glob­al CRO is build­ing a new R&D cen­ter next to an ex­ist­ing drug sub­stance man­u­fac­tur­ing site in the Jin­shan dis­trict — one of five owned by WuXi’s STA sub­sidiary — with 30,000 square me­ters of lab space. Plan­ning on a team of 500 sci­en­tists, WuXi is tout­ing the cen­ter as a one-stop shop for bio­phar­ma part­ners to push APIs and ad­vanced in­ter­me­di­ates from pre­clin­i­cal stage through com­mer­cial launch.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.